在中国的非控制性严重喘患者中使用dupilumab:成本效益分析
Zheng Liu1, Maosheng Xu2, Huifang Zhu1
1Department of Pharmacy, Shenzhen Baoan Women's and Children's Hospital, Shenzhen, 518102, People's Republic of China.
Journal of asthma and allergy
|October 9, 2025
概括
目前,在中国,对严重喘的杜皮卢马布补充治疗没有成本效益. 需要大幅降低dupilumab的价格,以提高患者的负担能力.
科学领域:
- 药物经济学 药物经济学
- 卫生技术评估 卫生技术评估
- 呼吸系统医学 呼吸系统医学
背景情况:
- 杜皮卢马布在中国已被批准用于治疗严重喘,但其成本效益尚未确定.
- 严重的喘管理需要新的治疗替代方案.
- 经济评估对于指导临床和治疗决策至关重要.
研究的目的:
- 在中国,对杜皮卢马布作为治疗非控制性严重喘的补充疗法进行成本效益分析.
- 为临床决策提供关于重症喘管理中dupilumab的证据.
- 与标准护理相比,评估dupilumab的经济价值.
主要方法:
- 一个马尔科夫模型模拟了五年的成本和质量调整寿命年 (QALYs).
- 该分析采用了12岁以上患者的医疗保健视角.
- 增量成本效益比 (ICUR) 与中国的人均GDP支付意愿 (WTP) 门 (13444.68美元/QALY) 进行了比较.
主要成果:
- 杜皮卢马布补充疗法导致更高的成本和更大的效用收益,ICUR为83,941.87美元/QALY,超过了WTP值.
- 敏感性分析确定了控制喘的实用性和dupilumab的价格是影响结果的关键因素.
- 标准护理疗法显示出更高的成本效益可接受性 (98.8%的概率).
结论:
- 目前,在中国,用于治疗失控严重喘的dupilumab补充治疗没有成本效益.
- 为了实现成本效益,需要大幅降低dupilumab的价格.
- 通过价格调整,可以提高dupilumab对这一患者群体的负担能力.
更多相关视频
05:34Author Spotlight: Utilizing Traditional Chinese Acupuncture of the Ear to Improve Sleep Disorders
Published on: August 18, 2023
3.3K
06:34A Component-resolved Diagnostic Approach for a Study on Grass Pollen Allergens in Chinese Southerners with Allergic Rhinitis and/or Asthma
Published on: June 4, 2017
10.4K
相关概念视频
01:30Asthma-IV: Diagnostic and Management
3.1K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.1K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
01:19Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K
01:26COPD: Management Using Bronchodilators and Corticosteroids
726
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
726